# SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

> **NCT07214818** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Mansoura University** · enrollment: 75 (estimated)

## Conditions studied

- Nephrotic Syndrome

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Empagliflozin
- **OTHER:** Standard Therapy

## Key facts

- **NCT ID:** NCT07214818
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-15
- **Primary completion:** 2026-07-05
- **Final completion:** 2026-09-06
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214818, "SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07214818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*